Catalyst Crew Technologies Corp. (OTC: CCTC) is advancing its telehealth platform in Venezuela, working through regulatory processes and initial deployment testing as part of its broader strategy to launch digital health solutions in emerging markets. The company announced Monday that it is actively evaluating system performance, user workflows, and operational capabilities through its digital interface at https://latamedai.org.
The platform is designed to support remote patient engagement, care coordination, and the integration of artificial intelligence-driven healthcare analytics tools. Current efforts focus on enhancing functionality, improving data integration, and optimizing the user experience. In parallel, the company is working with Venezuela's Ministerio del Poder Popular para la Salud, including the Servicio Autónomo de Contraloría Sanitaria (SACS), to obtain the required Permiso Sanitario de Funcionamiento para Plataforma Digital. The company is coordinating with authorities to address documentation, operational procedures, and compliance standards.
Management anticipates that the permitting process may be completed in the near term, though no assurance can be provided regarding timing or outcome. The company believes this phase of deployment, testing, and regulatory alignment is a critical step toward broader operational rollout across its target markets.
Dr. Kevin Rodan Levy, CEO of Catalyst Crew Technologies, stated: 'Our focus is on building a scalable telehealth platform that can operate effectively within real-world healthcare environments. We are currently advancing platform testing, refinement, and regulatory alignment as we continue to build the foundation for broader deployment across Latin America. We expect a full launch in short order and upon receiving all regulatory approvals.'
Catalyst Crew Technologies is a development-stage enterprise that has not generated revenues from its newly announced business direction. The company continues to advance its digital health and artificial intelligence platform, including telehealth infrastructure and AI-driven healthcare analytics. For more information, visit https://catalystcrewai.com or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
The implications of this announcement are significant for the company's strategic pivot into AI-enabled healthcare. Successfully obtaining regulatory approval and completing initial deployment in Venezuela would validate its platform in a real-world healthcare environment, potentially opening doors to broader adoption across Latin America. The company's focus on emerging markets, where healthcare infrastructure is often limited, positions it to address a growing demand for modernized delivery systems. However, as a development-stage enterprise with no revenues from its new direction, the company faces substantial risks, including the ability to secure financing, complete acquisitions, and comply with regulatory requirements. Investors should carefully consider these factors before making any investment decisions.
